The 20-year outcome of ascending aorta replacement and total arch replacement comparison in DeBakey type I acute aortic dissection

DeBakey I 型急性主动脉夹层患者行升主动脉置换术与全弓置换术 20 年疗效比较

阅读:2

Abstract

BACKGROUND: The mortality rate of acute DeBakey type I aortic dissection increases by 1%-2% every hour after the first presentation if left untreated. However, the long-term outcomes of ascending aorta replacement (AR) versus total arch replacement (TAR) remain unclear. This study evaluated and compared the long-term outcomes between AR and TAR. MATERIALS AND METHODS: This retrospective study included 398 patients with acute DeBakey type I aortic dissection who underwent surgical repair between March 2002 and October 2024. Patient data were extracted from medical records, and patients were stratified into two groups (AR and TAR groups) according to the surgical procedure. Inverse probability of treatment weighting was applied for further analysis. RESULTS: Higher incidences of acute kidney injury (32.3% vs 20.6%, P = 0.029), new-onset stroke (9.5% vs 3.7%, P = 0.016), and bleeding (30.1% vs 16.2%, P = 0.007) and longer hospital stays (34.4 vs 25.7 days, P = 0.042) were observed in the TAR group than in the AR group immediately postoperation. In long-term follow-up, no significant differences were observed between the groups regarding reintervention or mortality events. In addition, the risk of relative mortality associated with TAR was more apparent in patients older than 65 years. CONCLUSION: No significant differences were observed between TAR and AR in terms of 30-day mortality, reintervention events, aorta-related mortality, or overall mortality under the tear-oriented policy for acute DeBakey type I aortic dissection. Notably, older patients undergoing TAR had poorer overall survival outcomes than did those undergoing AR, particularly among patients older than 65 years.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。